Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen…
Novel T-cell therapy targeting an immunosuppressive receptor shows 50% response in treatment-resistant AML, with clues to improve outcomes through rational combination strategies.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small…
First-in-class drug targeting a tumor protein achieves 52% response in hard-to-treat lung cancer, substantially exceeding historical survival benchmarks for this disease.
Near-term implementable findingRenin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in…
Blood pressure medications widely used in sickle cell care worsen anemia by impairing red blood cell production, suggesting hemoglobin monitoring should become routine practice.
Early cancer detection or preventionChemotherapy for patients with circulating tumour DNA positive, stage…
Blood-based tumor DNA test identifies stage II colon cancer patients who benefit most from chemotherapy, pointing toward personalized treatment for traditionally undertreated subgroups.
Early cancer detection or preventionMultimodal analysis of cell-free DNA identifies epigenetic biomarkers…
Liquid biopsy detects ALS from a blood draw with 91% accuracy—far faster than the current 12+ month diagnostic odyssey—and tracks disease progression.